Panc 08.13 (ATCC® CRL-2551)

Organism: Homo sapiens, human  /  Cell Type: Epithelial  /  Tissue: pancreas  /  Disease: adenocarcinoma

Organism Homo sapiens, human
Tissue pancreas
Cell Type Epithelial
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1
Disease adenocarcinoma
Age 85 years
Gender male
Ethnicity White
Storage Conditions liquid nitrogen vapor phase
Derivation
Panc 08.13 is a pancreatic adenocarcinoma epithelial cell line derived in 1995 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
Clinical Data
85 years
male
White
Antigen Expression
MHC class I +; MHC class II -
Oncogene K-ras + RefJaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
Genes Expressed
cytokeratins 7 and 18
Cellular Products
cytokeratins 7 and 18
Tumorigenic Yes
Effects
Yes, forms tumors in nude or SCID mice
Comments
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine.
The cells have a reported plating efficiency of 40%.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium:
  • 10 Units/ml human recombinant insulin
  • fetal bovine serum to a final concentration of 15%

Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.53% (w/v) EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture Ratio: 1:2 to 1:4
Medium Renewal: Every 2 to 3 days.
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994

Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 11
D13S317: 13
D16S539: 13
D5S818: 13,14
D7S820: 11
THO1: 6,9.3
TPOX: 8,12
vWA: 18
Population Doubling Time 20 hrs
Name of Depositor EM Jaffee
Year of Origin 1995
References

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Basic Documentation
FAQ's
  1. Insulin solution for CRL-2549, CRL-2551 and CRL-2554


    Date Updated: 8/4/2014
References

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602